BUSINESS
Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
Takeda Pharmaceutical said on January 8 that it has sealed a global collaboration and license agreement with Halozyme Therapeutics to develop a new subcutaneous formulation of Entyvio (vedolizumab), using the US biotech’s ENHANZE drug-delivery technology. ENHANZE is based on Halozyme’s…
To read the full story
BUSINESS
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





